. 2016 May 28;22(20):4812–4823. doi: 10.3748/wjg.v22.i20.4812

Table 2.

Targeted therapy completed trials

Ref.	Name	Indication	Line	Arms	n	PFS (mo)	OS (mo)
Ref.	Phase	Indication	Line	Arms	n	PFS (mo)	OS (mo)
HER2
[28]	ToGA	HER2(+) Adv/Met GC and GEJ	1^st	Fluoropyrimidine/cisplatin ± trastuzumab	594	6.7 vs 5.5	13.8 vs 11.1
[28]	Phase III	HER2(+) Adv/Met GC and GEJ	1^st	Fluoropyrimidine/cisplatin ± trastuzumab	594	P = 0.0002	P = 0.0050
[29]	LOGiC	HER2(+) Adv/Met GC and GEJ	1^st	CapeOx ± lapatinib	545	6.4 vs 5.4	12.2 vs 10.5
[29]	Phase III	HER2(+) Adv/Met GC and GEJ	1^st	CapeOx ± lapatinib	545	p = 0.1000	P = 0.3492
[30]	TyTAN	HER2(+) Adv/Met GC and GEJ	2^nd	Paclitaxel ± lapatinib	261	5.4 vs 4.4	11.0 vs 8.9
[30]	Phase III	HER2(+) Adv/Met GC and GEJ	2^nd	Paclitaxel ± lapatinib	261	P = 0.2441	P = 0.2088
EGFR
[36]	EXPAND	Adv/Met GC and GEJ	1^st	Capecitabine/cisplatin ± cetuximab	904	4.4 vs 5.9	9.4 vs 10.7
[36]	Phase III	Adv/Met GC and GEJ	1^st	Capecitabine/cisplatin ± cetuximab	904	P = 0.3200	P = 0.9500
[37]	REAL3	Adv/Met GC and GEJ	1^st	EOX vs modified EOX + panitumumab	553	6.0 vs 7.4	8.8 vs 11.3
[37]	Phase III	Adv/Met GC and GEJ	1^st	EOX vs modified EOX + panitumumab	553	P = 0.0680	P = 0.013
VEGFR
[48]	Sunitinib	Adv GC and GEJ	2^nd	Sunitinib	78	2.3	6.8
[48]	Phase II	Adv GC and GEJ	2^nd	Sunitinib	78	2.3	6.8
[49]	Sunitinib	Adv GC and GEJ	2^nd or 3^rd	FOLFIRI ± sunitinib	91	3.6 vs 3.3	10.5 vs 9.0
[49]	Phase II	Adv GC and GEJ	2^nd or 3^rd	FOLFIRI ± sunitinib	91	P = 0.6600	P = 0.2100
[50]	Sorafenib	Adv/Met GC and GEJ	1^st	Docetaxel/cisplatin + sorafenib	44	5.8	13.6
[50]	Phase II	Adv/Met GC and GEJ	1^st	Docetaxel/cisplatin + sorafenib	44	5.8	13.6
[51]	Sorafenib	Adv GC and GEJ	2^nd	Oxaliplatin + sorafenib	40	3	6.5
[51]	Phase II	Adv GC and GEJ	2^nd	Oxaliplatin + sorafenib	40	3	6.5
[53]	Regorafenib	Adv GC and GEJ	2^nd or 3^rd	Regorafenib vs placebo	152	11.1 wk vs 3.9 wk	25 wk vs 19.4 wk
[53]	Phase II	Adv GC and GEJ	2^nd or 3^rd	Regorafenib vs placebo	152	P < 0.0001	P = 0.1100
[41]	AVAGAST	Adv GC and GEJ	1^st	Capecitabine/cisplatin ± bevacizumab	774	6.7 vs 5.3	12.1 vs 10.1
[41]	Phase III	Adv GC and GEJ	1^st	Capecitabine/cisplatin ± bevacizumab	774	P = 0.0037	P = 0.1002
[43]	REGARD	Met GC and GEJ	2^nd	BSC ± ramucirumab	355	2.1 vs 1.3	5.2 vs 3.8
[43]	Phase III	Met GC and GEJ	2^nd	BSC ± ramucirumab	355	P < 0.0001	P = 0.0473
[44,45]	RAINBOW	Met GC and GEJ	2^nd	Paclitaxel ± ramucirumab	665	4.4 vs 2.86	9.63 vs 7.36
[44,45]	Phase III	Met GC and GEJ	2^nd	Paclitaxel ± ramucirumab	665	P < 0.0001	P = 0.0169
[47]	Apatinib	Adv GC and GEJ	3^rd	Apatinib vs placebo	270	78 d vs 53 d	195 d vs 140 d
[47]	Phase III	Adv GC and GEJ	3^rd	Apatinib vs placebo	270	P < 0.0001	P < 0.016
mTOR
[58]	GRANITE-1	Adv GC and GEJ	2^nd or 3^rd	BSC ± everolimus	656	1.7 vs 1.4	5.4 vs 4.3
[58]	Phase III	Adv GC and GEJ	2^nd or 3^rd	BSC ± everolimus	656	P = 0.0010	P = 0.124

Adv: Advanced; Met: Metastatic; GC: Gastric cancer; GEJ: Gastroesophageal junction; CapeOx: Capecitabine/oxaliplatin; EOX: Epirubicin/oxaliplatin/capecitabine; FOLFIRI: Fluorouracil/leucovorin/irinotecan; BSC: Best supportive care; HER2: Human epidermal growth factor receptor 2; EGFR: Epidermal growth factor receptor; VEGFR: Vascular endothelial growth factor receptor; mTOR: Mammalian target of rapamyin.